Pharma Company Azitra Shoots Down "False Report" of a $44M Stock Offering

Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering. This report is false and should not be relied upon.

Azitra urges investors, stakeholders, and the public to rely only on information formally issued by the Company through its official channels. The Company is taking steps to identify the source of the false report.